Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review

Oluwaremilekun Tolu-Akinnawo1, David N Ray2, Tiwalade Awosanya3

  • 1Internal Medicine, Meharry Medical College, Nashville, USA.

Cureus
|August 7, 2024
PubMed

Insights

New device-based treatments are emerging to manage uncontrolled hypertension, offering alternatives to medication. These innovative approaches target the autonomic nervous system and other pathways to lower blood pressure effectively.

Area of Science:

  • Cardiovascular Medicine
  • Medical Devices
  • Interventional Cardiology

Background:

  • Hypertension is a leading modifiable risk factor for cardiovascular mortality, affecting 1.3 billion people globally.
  • Despite available medications, a significant portion of hypertensive patients remain uncontrolled.
  • New therapeutic strategies are needed to manage resistant hypertension and its complications.

Purpose of the Study:

  • To review current and emerging device-based interventions for arterial hypertension management.
  • To discuss recently approved and investigational devices modulating the autonomic nervous system and other physiological pathways.

Main Methods:

  • Review of recently FDA-approved devices, including renal denervation (RDN).
  • Discussion of investigational device-based therapies in clinical trials.
  • Categorization of devices by mechanism of action (e.g., neuromodulation, chemoreceptor modulation).

Main Results:

  • Two renal denervation (RDN) devices received FDA approval in November 2023.
  • Investigational devices show promising results in clinical testing for blood pressure reduction.
  • Various device classes target different physiological mechanisms, including autonomic nervous system activity.

Conclusions:

  • Device-based therapies represent a growing area for interventional hypertension management.
  • Emerging technologies offer new hope for patients with uncontrolled blood pressure.
  • Personalized approaches considering pathophysiology and procedural risks are crucial for device selection.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
41
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
517
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
147
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
151
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
666